Spinocerebellar ataxia type 17 (SCA17) is an inherited neurodegenerative disorder characterized by progressive ataxia, motor coordination disorders, and a variety of extrapyramidal symptoms. The disease is associated with mutations in the TBP (tavliaket protein) gene, which plays a key role in the regulation of transcription. The clinical picture of SCA17 includes ataxia, progressive loss of muscle tone, as well as cognitive impairment and psychosis. There are cases where the manifestations of the disease can develop at a later age, but the typical onset is in young or middle age. Since SCA17 belongs to the group of spinocerebellar ataxias, its progression often leads to severe dysfunction, requiring a comprehensive approach to diagnosis and treatment.
History of the disease and interesting historical facts
Spinocerebellar ataxia type 17 was first described in 2003 by a group of scientists including M. B. Nakada and colleagues, who distinguished this form of the disease from other types of spinocerebellar ataxia. The study of the genetic basis of SCA17 was made possible by improvements in genome sequencing technologies, which revealed a new mutation in the TBP gene. Subsequently, in 2004, it was found that an increased number of CAG repeats in this gene is pathognomonic for this type of disease. Interestingly, mutations in the TBP gene are also associated with other diseases, such as amyotrophic lateral sclerosis, highlighting the multifaceted nature and complexity of neurodegenerative disorders.
Epidemiology
The epidemiology of spinocerebellar ataxia type 17 remains poorly understood, but it is known to be a rare disease. According to various sources, the prevalence of SCA17 ranges from 0.6 to 1.4 cases per 100,000 population in European countries. In some regions, such as Japan, the incidence may be higher due to certain genetic predispositions. Penetration and age onset data also make it difficult to establish a clear picture of the epidemiology. In addition, it has been noted that women and men are affected with equal frequency.
Genetic predisposition to this disease
Spinocerebellar ataxia type 17 is caused by an expansion of CAG repeats in the TBP gene, which is located on chromosome 6. The normal variant of the gene contains 25 to 40 repeats, while in patients with SCA17 the number of repeats can exceed 40 and even reach 70. The increase in repeats leads to a disruption in the function of the protein, which in turn affects neurodegenerative processes. This mutation is inherited in an autosomal dominant manner, which means that only one mutant allele is necessary for the disease to manifest. The unpredictability of the repeat gains makes genetic counseling of great importance for potential carriers.
Risk factors for the development of this disease
The main risk factor for developing spinocerebellar ataxia type 17 is a genetic predisposition, namely the presence of a mutation in the TBP gene. Additional risk factors may include:
- Age: The disease usually appears between the ages of 30 and 50 years.
- Family history: presence of other people with SCA in the family.
- Environment and ecology: Toxic factors (eg, heavy metals) may aggravate symptoms.
At present, the main external factors contributing to the development of the disease have not been identified.
Diagnosis of this disease
Diagnosis of spinocerebellar ataxia type 17 is based on clinical examination and a comprehensive approach to assessing the patient's condition. The main symptoms of the disease include:
- Progressive ataxia;
- Coordination disorders;
- Muscle weakness;
- Cognitive disorders;
- Depression and psychosis.
Laboratory testing includes genetic testing for mutations in the TBP gene. Radiologic tests, such as magnetic resonance imaging (MRI), may show atrophy of the cerebellum and other structures. The differential diagnosis should include other forms of spinocerebellar ataxia and neurologic diseases such as Huntington's disease or Neider syndrome.
Treatment
Treatment of spinocerebellar ataxia type 17 is mainly symptomatic. There are currently no effective methods to stop the progression of the disease. The main approaches are as follows:
- General treatment: rehabilitation measures, physical therapy and coordination training;
- Pharmacological treatment: antidepressants and anti-anxiety drugs are used to control mental disorders;
- Surgical treatment: In some cases, cerebellar surgery may be considered to reduce symptoms;
- Other types of treatment: use of assistive devices (canes, wheelchairs, etc.).
List of medications used to treat this disease
Medications that may be used to relieve symptoms of SCA17 include:
- Selective serotonin reuptake inhibitors (SSRIs): eg, sertraline;
- Non-complex anti-anxiety drugs: clonazepam;
- Some antipsychotic drugs: olanzapine;
- Cat's Claw (Uncaria tomentosa) to support nerve function.
Disease monitoring
Monitoring of patients with spinocerebellar ataxia type 17 includes regular examinations and assessment of symptom progression. Follow-up visits should be performed every 6 to 12 months and include assessment of functional capacity, cognitive function, and general condition of the patient. The prognosis for patients with this disorder varies and depends on the time of onset, severity of symptoms, and the presence of comorbidities. Complications may include: complete loss of self-care, rigid muscle contractures, and severe mental disorders.
Age-related features of the disease
Spinocerebellar ataxia type 17 can manifest itself in different age groups with characteristic differences in the clinical course:
- Young patients (under 30 years): most often have more rapid disease progression;
- Middle-aged patients (30-50 years): cognitive impairment and psychosis are more common;
- Elderly patients (over 50 years): more pronounced movement disorders with lesser cognitive impairment may be observed.
Questions and Answers
- What are the main symptoms of spinocerebellar ataxia type 5? The main symptoms include progressive ataxia, loss of coordination, muscle weakness, cognitive impairment and psychosis.
- How is SCA17 diagnosed? Diagnosis is based on clinical assessment of symptoms, genetic testing and magnetic resonance imaging.
- Is there a treatment for SCA17? Treatment is mainly symptomatic, including physical rehabilitation and pharmacological therapy to control psychiatric symptoms.
- What is the heritability of this disease? SCA17 is inherited in an autosomal dominant manner, meaning that one mutant allele is sufficient to cause the disease.
- What are the risk factors for SCA17? The main risk factor is the presence of a mutation in the TBP gene, as well as a family history of the disease.
